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Received February 25, 2013; accepted June 28, 2013AbstractChronic visceral pain is the predominant symptom of functional gastrointestinal disorders and chronic pancreatitis. Such pain can impair the
patients’ quality of life, and can also serve as one of the principal reasons for these patients to seek medical help. Nevertheless, the underlying
mechanisms of chronic visceral pain have remained unclear, and much of what we know about visceral pain has been derived from studies of
somatic nociception. Current treatment of chronic visceral pain has continued to be unsatisfactory, because of unclear pathophysiology.
However, recent progress in pain research has identified the important role of spinal microglia in the development of somatic nociception. For
visceral pain, several animal studies have demonstrated that spinal cord microglia is activated during the development of visceral hyperalgesia,
which can be induced by neonatal colorectal irritation, psychological stress, and trinitrobenzene sulfonic acid-induced pancreatitis. This visceral
hyperalgesia is also associated with elevated phosphorylation of p38 mitogen-activated protein kinase. Minocycline (a microglia inhibitor)
reversed the hyperalgesia in rat models of chronic visceral pain, whereas fractalkine (FKN, a microglia activator) reproduced the visceral
nociception in naı¨ve rats. These preliminary results support the pronociceptive role of spinal microglia in mediating visceral hyperalgesia.
Consequently, spinal microglia may serve as a promising target for controlling the chronic visceral pain.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Visceral pain is one of the most common forms of pain
produced by diseases arising from the bowel or internal or-
gans. Additionally, visceral pain is one of the most frequent
complaints that provokes patients to seek medical help.1
Notwithstanding these facts, much of the current knowledge
about the visceral pain mechanisms of pain is mainly derived
from experimental studies in somatic nociception.2,3 Although
the pain processes between visceral and somatic nociception
have much in common, they also have several important dif-
ferences.3 First, visceral pain is less localized, and is more
unpleasant than perceived intensity-matched somatic pain.* Corresponding author. Dr. Ching-Liang Lu, Division of Gastroenterology,
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Taiwan, ROC.
E-mail addresses: cllu@ym.edu.tw, cllu@vghtpe.gov.tw (C.-L. Lu).
1726-4901/$ - see front matter Copyright  2013 Elsevier Taiwan LLC and the C
http://dx.doi.org/10.1016/j.jcma.2013.08.008Second, visceral pain can be manifested in other locations and
is usually accompanied by motor and autonomic reflexes, such
as nausea, vomiting, and lower-back muscle tension that
typically occurs in renal colic.4 Furthermore, visceral pain
cannot be evoked from all viscera. Organs such as the liver,
kidney, most solid viscera, and lung parenchyma are not
sensitive to pain.3
Chronic visceral pain is the predominant symptom of
functional gastrointestinal disorder (FGID).5 FGID accounts
for more than half of the patient traffic in GI clinics. Despite
extensive research in this area, the pathophysiology of the
origin of visceral pain in patients with FGID remains uncer-
tain, a fact which contributes to unfavorable treatment out-
comes. The lack of an identified biomarker and firm diagnosis
in FGID also results in the increased cost of medical care,
loss of work productivity, and impairment of quality of life
(QoL) in FGID patients. The combination of extensive
investigation and frequent hospital attendance exerts ahinese Medical Association. All rights reserved.
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resources, and impacts economies in both Western and Eastern
countries.6e8 Another common form of chronic visceral pain
is the pain from chronic pancreatitis (CP). Chronic epigastric
pain is the cardinal feature of CP, which is usually recurrent,
intense, and long-lasting. The pain in CP can lead to malnu-
trition, narcotic addiction, and major socio-economic prob-
lems. However, the control of pain in CP remains a difficult
and frustrating challenge for clinicians.9 Similar to the situa-
tion in FGID, the underlying mechanisms by which pain in CP
is produced are still unclear.
The pathological pain seen in FGID or CP is usually
accompanied by visceral hyperalgesia and allodynia, resulting
in a heightened response to noxious or even non-noxious
stimuli. The abnormal nociceptive responses can be induced
by the neuroplastic changes in primary afferent fibers (pe-
ripheral sensitization), as well as in the spinal cord and brain
(central sensitization).5,10 Recent research has demonstrated
that persistent activation of spinal microglia may contribute to
chronic pain after peripheral and central nervous system
(CNS) injury; these findings suggest that treatment by target-
ing microglia may attenuate or alleviate chronic pain syn-
drome.11,12 However, most reports on the contribution of
microglia to pain focus on somatic rather than visceral forms
of chronic pain. Thus, we will present a brief review starting at
the current understanding of the roles of microglia cells in
chronic somatic pain, and then in visceral pain.
2. Overview of glia cells
Glial cells, including microglia, astrocytes, and oligoden-
drocytes in the CNS, have all been considered as the “third
element” that simply fills spaces around neurons, the “truly”
functional cells of the nervous system.13 It is widely accepted
that glia maintain general homeostasis of the CNS in ways that
impact on neuronal function.12,14 Oligodendrocytes are
responsible for myelin formation in axons. Astrocytes, neu-
roectoderm in origin and contributing to around 40e50% of
all glia cells, are thought to play roles in the regulation of
potassium, glutamate, and other neurotransmitters in the CNS.
Astrocytes would also be activated upon various stimuli and in
response to the many byproducts from activated microglia. For
microglia, it originates from bone-marrow derived monocytes,
and shares a common mesodermal lineage with macrophages.
Microglia constitutes about 5e12% of the total glial cell
population and is traditionally viewed as the phagocytes in the
CNS. Under normal conditions, microglia is in a quiescent
status and can be activated or mobilized upon injury, infection,
or other diseases states in the CNS.
3. Spinal microglia in chronic neuropathic or
inflammatory pain
Traditionally, plastic changes in neurons are thought to play
a major role in the sensitization of nociceptive pathways in
both chronic somatic and visceral pain. In recent years, the
link between microglia and pathological pain states hasbecome more widely acknowledged.11,13,15 Microglia activa-
tion has been found to play a key role in the initiation and/or
maintenance of hyperalgesia and allodynia in animal models
of chronic neuropathic or inflammatory pain.12,14,16e19
Microglia can display significant morphology changes
(from ramified to ameboid) in a chronic pain model after pe-
ripheral nerve injury (such as nerve transaction or ligation of
the sciatic nerve), peripheral inflammation (intra-articular in-
jection of complete Freund’s adjuvant), or damage to the CNS
(spinal cord injury and spinal infection with human immu-
nodeficiency virus).20e28 Persistent hyperalgesia and allody-
nia, as well as release of many pro-inflammatory mediators,
can be observed in association with morphological changes of
the spinal microglia. Multiple mechanisms may be involved in
the activation of spinal microglia during somatic pain pro-
cessing. Several pathways with associated molecules are re-
ported to be involved in the somatic nociception, such as: (1)
chemokine X3C-1 receptor [CX3CR-1, with fractalkine
(FKN) as ligand]; (2) interferon-gamma receptor (IFN-gam-
maR); (3) toll-like receptor; and (4) purinergic receptor.12 The
molecules mentioned have been administered to rodent models
and shown to alter chronic pain behaviors. For example, spinal
nerve injury will induce an up-regulation of CX3CR1 in spinal
microglia.29 Following peripheral nerve injury, FKN has been
found to be released from primary afferents and then bind to
its CX3CR1, expressed predominantly in spinal cord micro-
glia, to induce microglial activation.11,30,31 Thus, FKN can act
as a signal between neuron and microglia to induce microglia
activation. For IFN-gammaR, rosiglitazone, a peroxisome
proliferator-activated receptor-gamma agonist showing an
ability to down-regulate IFN-gamma-induced gene expression
and subsequent reduction of the chemotactic response to
chemokine ligand 2, can attenuate the tactile allodynia in a
neuropathic pain model.32 Toll-like receptors (TLRs) are a
family which includes 13 receptors that play a key role in the
innate immune system to defend the host against pathogens.
TLR2 has been shown to play a critical role in morphine-
induced microglia activation and dependence.14 Spinal TLR4
mRNA expression in microglia was increased after L5 nerve
transaction in rats, a model of neuropathic pain.33 And TLR-4
knockout mice developed less neuropathic pain, as well as
strongly decreased expression of pain-related cytokines.34
ATP and its purinergic receptors (P2) are well-known pain
mediators.35 Spinal up-regulation of P2X4 in microglia has
been demonstrated to be crucial for tactile allodynia after
peripheral nerve injury.36 Furthermore, pharmacological inhi-
bition or genetic deletion of either P2X4 or P2Y12 alleviates
allodynia or heat hyperalgesia after peripheral nerve
injury.37,38 In addition to these major pathways in mediating
microglia activation in a chronic somatic pain model, other
molecules may also be involved in the somatic nociception.
These molecules include MHC class II proteins, glucocorti-
coid receptors, and cannabinoid type 1 or 2 receptors.11,12,15
Once microglia is activated, the activated microglia would
increase synthesis and secretion of various cytokines and
chemokines, including IL-1b, IL-6, IL-10, tumor necrosis
factor (TNF), prostaglandin E2 (PGE2), nitric oxide, and
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microglia-released cytokines will also amplify microglia
activation themselves in an autocrine manner.12 In addition,
the cytokines may also directly modulate dorsal horn neuron
activity involved in the development of pain hypersensitivity.
Evidence has also shown that intrathecal injection of cyto-
kines, such as IL-1b, IL6, or TNF-a, can lead to symptoms of
neuropathic pain in naı¨ve rats.40 Furthermore, microglia acti-
vation may partially contribute to the induction of the ATP
receptors (P2X4, P2X7), p38 phosphorylation, and IL-1
release.41,42 The above cross-talk between neurons and
microglia would play a role in mediating pain behavior
sensitization. Besides the cross-talk between microglia and
neurons in the pathogenesis of somatic nociception, it has been
suggested that astrocytes may also play a role in the initiation
and maintenance of chronic pain.12 Activated astrocytes can
also release cytokines and chemokines to enhance and prolong
the nociceptive responses.
The intracellular signaling pathways mediating spinal
microglia activation in response to cytokines have also been
explored. Increased p38 phosphorylation in spinal microglia
(activated MAPK pathway) has been demonstrated in an ani-
mal model of pathological pain from peripheral inflammation,
nerve injury, and spinal cord injury.8 Pharmacological inhibi-
tion of p38 activity can attenuate the development of allodynia
and hyperalgesia in various somatic pain models.20,26,43 Be-
sides p38 activation, extracellular signal-regulated kinase and
the nuclear transcription factor NF-kB have been described as
the important mediators involved in the intracellular signaling
pathways and transcription regulation of the genes encoding
for proinflammatory cytokines in spinal microglia after nerve
injury.44,45 This phenomenon provides positive feedback loops
in the crosstalk between microglia and neurons, leading to
more production of the inflammatory mediators and sequent
central sensitization.
The above evidence suggests that microglia plays a crucial
role in the development of somatic pain. Thus, immunosup-
pressive compounds are then developed to attenuate microglialFig. 1. Microglia activity (OX-42 immunofluorescence statin) in the spinal dorsal h
intraductal injection-induced chronic pancreatitis (scale bar ¼ 100 mm).activation, and proved to be effective in relieving neuropathic
pain in animal models. For example, minocycline can selec-
tively inhibit microglia, suppress the release of proin-
flammatory cytokines and p38 phosphorylation, and ultimately
be effective in attenuating the neuropathic pain in animal
models.46e49 Despite the positive effect of minocycline in the
treatment of ongoing pain, controversial results exist. For
example, in the L5 spinal nerve transection model, the initi-
ation of minocycline treatment 5 days after transection does
not attenuate allodynia and hyperalgesia, although it does
inhibit microglial activation.50 Similarly, systemic adminis-
tration of minocycline has no effect on phase 2 formalin-
induced flinching or carrageenan-induced hyperalgesia.46
Interestingly, intrathecal minocycline did reduce the periph-
eral inflammation-induced hyperalgesia.46 Minocycline is also
not effective in reversing allodynia after sciatic nerve
inflammation if the drug is given 1 week after onset, even
though minocycline did show some effect at the initial phase
of allodynia.47 The reason for these widely different results is
still unclear and further studies are necessary to better explain
the contradictory results.
4. Spinal microglia in chronic visceral pain
Although visceral pain is an important component of the
normal sensory function of a human being, surprisingly, the
study of the role of spinal microglia in chronic visceral pain is
extremely rare and has only recently been addressed. Saab
et al4 first found activated microglia (increased spinal immune
reactivity for OX-42) in a rat model with chronic visceral
hyperalgesia, induced by neonatal colon irritation by repeated
colorectal distension using an angioplasty balloon; the model
could exhibit both peripheral and central sensitization. Using
minocycline to interrupt microglia activation and its associated
release of proinflammatory mediators would reverse the
visceral pain behavior and restore normal processing of
neuronal information along the visceral pain pathway in
adulthood.orn of rats in (A) resting status; and (B) trinitrobenzene sulfonic acid (TNBS)
Fig. 2. Schematic illustration of the role of spinal microglia in mediating visceral hyperalgesia in a rat model of trinitrobenzene sulfonic acid (TNBS)-intraductal
injection to induce chronic pancreatitis (CP). Minocycline can inhibit and prevent the microglia activation and the associated visceral hyperalgesia in TNBS-
induced CP rat model.
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intracolonic instillation to induce severe gut inflammation,
marked microglia activation and increased levels of tumor
necrosis factor-a were noted in the hippocampus.51 Although
nociceptive behavior was not recorded in this report, visceral
hyperalgesia is expected to be observed in the TNBS-treated
rats.52 This study also provided evidence of supraspinal acti-
vation of microglia upon gut inflammation, although its role in
mediating visceral hyperalgesia remains to be clarified.
In another “non-inflammatory” model of visceral hyper-
algesia, Bradesi et al44 found that chronic psychological stress
(water avoidance 1 hour/day for 10 consecutive days) can also
lead to microglia activation in the lumbar spinal cord.
Increased spinal immunoreactivity of P-p38 MAPK in OX42
positive cells was also noted from stressed rats, which can be
blocked by minocycline. They also demonstrated that the
stress-induced visceral hyperalgesia can be reversed by min-
ocycline or the p38 inhibitor, SB203580. Furthermore, spinal
injection of FKN (a microglia activator) in naı¨ve rats can also
induce visceral hyperalgesia, and this finding further supports
the role of spinal microglia in mediating this stress-induced
visceral hyperalgesia.
Recently, we first showed that activation of spinal microglia
can play a key role in both initiating and maintaining visceral
hyperalgesia in a TNBS-induced CP rat model.53 The spinal
microglia showed morphological changes (ameboid cells) with
an increase in OX42 staining in the dorsal horn of the thoracic
spinal cord in CP rats (Fig. 1). P-p38 levels were also
increased in CP rats and colocalized with OX42-positive cells,Fig. 3. Schematic illustration of the molecular and cellular mechanisms in the acbut in neither NeuN-positive (neuron) nor GFAP-positive
(astrocyte) cells. Intrathecal injection of minocycline would
not only reverse, but also prevent the increase of nocifensive
behaviors and P-p38 levels in CP rats (Fig. 2). FKN would
induce visceral hyperalgesia in non-CP rats, which was also
blocked by minocycline. We also found that the spinal Ik-B
level was significantly decreased after TNBS-induced
pancreatitis; the Ik-B level reversed to normal after minocy-
cline treatment (unpublished data). This finding suggests the
importance of NF-kB signaling pathway in microglia-
mediated visceral nociception. We further noted that the spi-
nal level of P2X7R, colocalized with OX-42, was significantly
increased after CP (unpublished data). Pharmacological or
genetic manipulation of P2X7 receptor by administration of a
P2X7 antagonist (Brilliant Blue G) and siRNA to P2X7R
would significantly reduce the visceral hyperalgesia in CP rats.
These results indicate an important role of P2X7R on spinal
microglia in mediating visceral hyperalgesia in a CP rat
model. Taken together the current data, although limited when
compared with available data from somatic pain studies,
strongly supports the role of spinal microglia in the trans-
mission of visceral nociception. Although some differences do
exist in the pain process between visceral and somatic pain,
spinal microglia may play an important and common role in
the pathogenesis of both types of pain.
In conclusion, chronic visceral pain from FGID or CP
creates a significant burden on society, as well as on individual
patients. Because of unclear pathogenesis and poorly identi-
fied targets, the current treatment for chronic visceral pain hastivation of spinal microglia in visceral, neuropathic, and inflammatory pain.
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the involvement of microglia in the development and main-
tenance of chronic visceral and somatic pain (Fig. 3). Further
studies focusing on microglia (such as tetracycline or Brilliant
Blue G) during nociception may provide a promising strategy
to identify novel targets for the treatment of chronic visceral
pain in those patients with FGID or CP.
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